{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-250984","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.616580+00:00","generated_at":"2026-05-30T05:18:28.616395+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Karyopharm Q3 total revenue $38.8M, net loss $32.1M; narrows FY2024 guidance","bullets":["U.S. XPOVIO net product revenue $29.5M in Q3, down from $30.2M in Q3 2023; total revenue up to $38.8M from $36.0M.","Net loss $32.1M ($0.26/share) vs $34.5M ($0.30/share) in Q3 2023; R&D expenses increased to $36.1M.","FY2024 total revenue guidance narrowed to $145-155M; XPOVIO revenue guidance narrowed to $110-115M.","Phase 3 SENTRY myelofibrosis trial endpoint changed to Abs-TSS; sample size increased to ~350; top-line data expected 2H 2025.","Cash and investments $133.9M; cash runway into Q1 2026 (excluding $24.5M convertible note due Oct 2025)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-250984","json":"https://secwatch.observer/filing/0001193125-24-250984.json","markdown":"https://secwatch.observer/filing/0001193125-24-250984.md","text":"https://secwatch.observer/filing/0001193125-24-250984.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524250984/0001193125-24-250984-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524250984/d906207d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:18:28.616395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}